

Tanka[®]

Wellness Made Simple

T-MIGRAINE

CLINICAL
TRIAL



TANKA T-MIGRAINE

never-before seen approach innovative transdermal medical device as a disruptive supplement delivery system tanka's solution is a unique delivery device in the shape of a bracelet that serves as a reservoir to release and deliver, trans-dermally, active ingredients to **relief migraine episodes and frequent headache.**

Relief was observed after 9 Days*

T-MIGRAINE,

transdermal medical device contains scientifically formulated blend: Feverfew, Butterbur and Valerian oil.

T-MIGRAINE

includes a specially designed combination of efficient active ingredients **with synergistic effect** – each playing a unique and critical role.

CLINICAL TESTS :


- ▶ 22 volunteers, aged from 27 to 66 years (mean 44.5 ± 11.3) were initially recruited for a human use test with Bracelet T-Migraine after topical treatment for 8 weeks (wearing 1 bracelet per month in one of the wrists). The volunteers were required to be between 30 and 65 years, with frequent headache and migraine episodes (≥ 56 in scale HIT-6 for headache and ≥ 2 in positive responses for ID Migraine Test), without using any medical treatment 15 days before and/or during the study.
- ▶ After 28 and 56 days of treatment, subjects attended clinical facilities and participant's subjective perception of the product efficacy was assessed with an individual questionnaire. The ordinal scale used was (1 = Poor | 2 = Fair | 3 = Good | 4 = Very good | 5 = Excellent). Satisfaction was considered for scores 3 - 5, and a remarkable percentage of acceptance was considered when average result is ≥ 80 %.

RESULTS:

Data indicated an overall acceptance of 77.9 and 83.0, after 28 and 56 days of treatment, respectively. Specifically, significant positive evaluations (overall acceptance ≥ 80 %) were obtained for 6 out of 15 items after 4 weeks of treatment and 12 out of 15 items after 8 weeks. none of the 22 volunteers initially recruited showed any acceptability problem neither manifested any adverse symptom or Serious Undesirable Effects (SUE) throughout the period of treatment or the following 7 days.

CONCLUSION:

The topical application with “Bracelet T-Migraine” for 8 weeks in 22 volunteers shows good cutaneous compatibility and may claim “Clinically Tested”, and “Tolerance Tested”. With regard to the volunteers’ perception, data indicated an overall acceptance of 77.9 and 83.0, after 28 and 56 days of treatment, respectively.



Tanka®



Wellness Made Simple

T-MIGRAINE

CLINICAL
TRIAL



For more information please contact

 info@tankaltd.com or visit our website  www.tankaltd.com